TPTX » Topics » and 240.24b-2.

This excerpt taken from the TPTX 8-K filed Oct 10, 2006.

and 240.24b-2.

 

August 26, 2004

 

 

Neurogenetics, Inc.

11085 N. Torrey Pines Road

La Jolla, California 92037

Attention:  Chief Executive Officer

 

Ladies and Gentlemen:

 

As you are aware, we have been engaged in discussions, and as of the date of this letter we are entering into an equity investment in Neurogenetics, Inc., a Delaware corporation (the “Company” or “you”), by Johnson & Johnson Development Corporation, a New Jersey corporation (“JJDC” or “we” or “us”), pursuant to that certain Series C Participating Preferred Stock Purchase Agreement of even date herewith by and among JJDC, the Company and the certain other investors set forth therein. The purpose of this letter is to provide JJDC with certain rights with respect to the consummation of any proposed sale, transfer, license or distribution arrangement, whether by operation of law or by merger or consolidation, regarding any of the Rights (as defined below (any of such transactions referred to above being hereinafter referred to as a “Proposed Transaction”). The term “Rights” shall include all inventions, developments, patents, patent applications, know-how, technology, other proprietary rights or products owned, developed or acquired (whether through license or otherwise) by the Company related to its research and development work into the use of M1 agonists in the treatment of CNS disorders (the “M1 Agonist Program”). JJDC’s affiliate company Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (“J&J PRD”) has [***] and [***], which are part of the M1 Agonist Program, and based thereon, JJDC has elected to enter into this letter agreement with the Company. In consideration of the representations, warranties, agreements and covenants contained in this letter, and for other good and valuable consideration, including the agreement of Scott Reines, Vice President at J&J PRD, or such other person as may be designated by JJDC, and reasonably acceptable to the Company, to serve without compensation (other than reimbursement of reasonable expenses) as a scientific advisory board or clinical advisory board member to the Company through December 31, 2005 pursuant to a mutually acceptable scientific advisory board or clinical advisory board consulting agreement, the receipt and sufficiency of which are hereby acknowledged, JJDC and the Company hereby agree as follows:

 

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki